- Investing Ideas
- /
- South Korean Pharmaceuticals & Biotech Undervalued based on future growth
South Korean Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
Hugel
Market Cap: ₩2.5t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩230,000.00
7D
-0.2%
1Y
-12.9%
L&C BIOLTD
Market Cap: ₩1.5t
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine.
A290650
₩60,500.00
7D
-1.0%
1Y
125.7%
Medy-Tox
Market Cap: ₩846.6b
Operates as a biopharmaceutical company in South Korea.
A086900
₩120,600.00
7D
-0.2%
1Y
-2.9%
DongKook Pharmaceutical
Market Cap: ₩766.4b
Produces and sells pharmaceutical products in South Korea and internationally.
A086450
₩17,130.00
7D
-0.1%
1Y
7.2%
Dong-A Socio Holdings
Market Cap: ₩687.3b
Engages in the pharmaceutical business in South Korea.
A000640
₩106,800.00
7D
-2.6%
1Y
5.5%